Published in Magn Reson Med on October 15, 2013
Free-breathing 3D late gadolinium enhancement imaging of the left ventricle using a stack of spirals at 3T. J Magn Reson Imaging (2014) 0.82
Accelerated free breathing ECG triggered contrast enhanced pulmonary vein magnetic resonance angiography using compressed sensing. J Cardiovasc Magn Reson (2014) 0.77
Clinical performance of high-resolution late gadolinium enhancement imaging with compressed sensing. J Magn Reson Imaging (2017) 0.75
SENSE: sensitivity encoding for fast MRI. Magn Reson Med (1999) 29.55
Sparse MRI: The application of compressed sensing for rapid MR imaging. Magn Reson Med (2007) 22.30
Generalized autocalibrating partially parallel acquisitions (GRAPPA). Magn Reson Med (2002) 20.68
The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med (2000) 13.25
An improved MR imaging technique for the visualization of myocardial infarction. Radiology (2001) 7.45
Undersampled radial MRI with multiple coils. Iterative image reconstruction using a total variation constraint. Magn Reson Med (2007) 7.10
Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement. Magn Reson Med (2002) 4.95
Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation (2009) 4.33
New magnetic resonance imaging-based method for defining the extent of left atrial wall injury after the ablation of atrial fibrillation. J Am Coll Cardiol (2008) 3.67
Self-gated cardiac cine MRI. Magn Reson Med (2004) 2.97
Respiratory motion of the heart: kinematics and the implications for the spatial resolution in coronary imaging. Magn Reson Med (1995) 2.69
Free-breathing whole-heart coronary MRA with 3D radial SSFP and self-navigated image reconstruction. Magn Reson Med (2005) 1.82
Pathophysiology of dyspnea. N Engl J Med (1995) 1.61
Diaphragmatic and cardiac motion during suspended breathing: preliminary experience and implications for breath-hold MR imaging. Radiology (1998) 1.51
Low-dimensional-structure self-learning and thresholding: regularization beyond compressed sensing for MRI reconstruction. Magn Reson Med (2011) 1.41
Delayed contrast enhancement on MR images of myocardium: past, present, future. Radiology (2011) 1.38
Motion-corrected free-breathing delayed enhancement imaging of myocardial infarction. Magn Reson Med (2005) 1.32
Breath-holding and its breakpoint. Exp Physiol (2005) 1.21
Respiratory self-gated four-dimensional coronary MR angiography: a feasibility study. Magn Reson Med (2008) 1.15
Breath-holding in healthy and pulmonary-compromised populations: effects of hyperventilation and oxygen inspiration. J Magn Reson Imaging (1997) 1.13
Phase-sensitive inversion-recovery MR imaging in the detection of myocardial infarction. Radiology (2005) 1.10
Myocardial viability: breath-hold 3D MR imaging of delayed hyperenhancement with variable sampling in time. Radiology (2004) 1.07
A fast navigator-gated 3D sequence for delayed enhancement MRI of the myocardium: comparison with breathhold 2D imaging. J Magn Reson Imaging (2008) 1.05
Accelerated late gadolinium enhancement cardiac MR imaging with isotropic spatial resolution using compressed sensing: initial experience. Radiology (2012) 1.05
Myocardial viability: rapid assessment with delayed contrast-enhanced MR imaging with three-dimensional inversion-recovery prepared pulse sequence. Radiology (2003) 1.00
Left ventricular infarct size, peri-infarct zone, and papillary scar measurements: A comparison of high-resolution 3D and conventional 2D late gadolinium enhancement cardiac MR. J Magn Reson Imaging (2009) 0.98
Fast, three-dimensional free-breathing MR imaging of myocardial infarction: a feasibility study. Magn Reson Med (2004) 0.95
Pulmonary vein inflow artifact reduction for free-breathing left atrium late gadolinium enhancement. Magn Reson Med (2011) 0.94
Navigator-gated and real-time motion corrected free-breathing MR Imaging of myocardial late enhancement. Rofo (2002) 0.94
Acute, subacute, and chronic myocardial infarction: quantitative comparison of 2D and 3D late gadolinium enhancement MR imaging. Radiology (2011) 0.93
Role of chemoreceptors in mediating dyspnea. Respir Physiol Neurobiol (2008) 0.93
Myocardial viability: assessment with three-dimensional MR imaging in pigs and patients. Radiology (2006) 0.92
Breath-holding capability of adults. Implications for spiral computed tomography, fast-acquisition magnetic resonance imaging, and angiography. Invest Radiol (1994) 0.91
Breath holding after breathing of oxygen. J Appl Physiol (1959) 0.90
Free-breathing delayed hyperenhanced imaging of the myocardium: a clinical application of real-time navigator echo imaging. J Magn Reson Imaging (2006) 0.84
Assessment of Myocardial Viability with 3D MRI at 3 T. AJR Am J Roentgenol (2009) 0.84
Respiratory bellows-gated late gadolinium enhancement of the left atrium. J Magn Reson Imaging (2012) 0.84
Coronary MR angiography: true FISP imaging improved by prolonging breath holds with preoxygenation in healthy volunteers. Radiology (2003) 0.83
Navigator assessment of breath-hold duration: impact of supplemental oxygen and hyperventilation. AJR Am J Roentgenol (1998) 0.82
Free-breathing MRI for the assessment of myocardial infarction: clinical validation. AJR Am J Roentgenol (2009) 0.81
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA (2012) 5.27
American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr (2004) 4.88
Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol (2008) 4.51
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01
Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation (2008) 3.77
Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation (2003) 3.20
Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. Eur Heart J (2004) 3.19
Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 3.11
Detection of pulmonary vein and left atrial scar after catheter ablation with three-dimensional navigator-gated delayed enhancement MR imaging: initial experience. Radiology (2007) 2.93
Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol (2008) 2.82
Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging (2012) 2.76
Intermediate-signal-intensity late gadolinium enhancement predicts ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy. Circ Cardiovasc Imaging (2011) 2.54
Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J (2012) 2.42
Gender differences and normal left ventricular anatomy in an adult population free of hypertension. A cardiovascular magnetic resonance study of the Framingham Heart Study Offspring cohort. J Am Coll Cardiol (2002) 2.33
Recurrence of atrial fibrillation correlates with the extent of post-procedural late gadolinium enhancement: a pilot study. JACC Cardiovasc Imaging (2009) 2.33
ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol (2010) 2.23
[IV Brazilian Guideline for Dyslipidemia and Atherosclerosis prevention: Department of Atherosclerosis of Brazilian Society of Cardiology]. Arq Bras Cardiol (2007) 2.19
ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation (2010) 2.14
"Soap-Bubble" visualization and quantitative analysis of 3D coronary magnetic resonance angiograms. Magn Reson Med (2002) 2.09
Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation (2011) 2.04
Cardiovascular magnetic resonance characterization of mitral valve prolapse. JACC Cardiovasc Imaging (2008) 1.87
Preliminary report on in vivo coronary MRA at 3 Tesla in humans. Magn Reson Med (2002) 1.82
Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation (2006) 1.69
Nkx2.5 homeoprotein regulates expression of gap junction protein connexin 43 and sarcomere organization in postnatal cardiomyocytes. J Mol Cell Cardiol (2003) 1.67
Prevalence of non-cardiac pathology on clinical transthoracic echocardiography. J Am Soc Echocardiogr (2012) 1.67
Correlation of trabeculae and papillary muscles with clinical and cardiac characteristics and impact on CMR measures of LV anatomy and function. JACC Cardiovasc Imaging (2012) 1.66
Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation (2009) 1.66
Pericardial fat, intrathoracic fat, and measures of left ventricular structure and function: the Framingham Heart Study. Circulation (2009) 1.65
Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. J Am Coll Cardiol (2013) 1.60
Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail (2008) 1.58
Cardiac index is associated with brain aging: the Framingham Heart Study. Circulation (2010) 1.57
ACCF/AHA clinical competence statement on cardiac imaging with computed tomography and magnetic resonance: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training. J Am Coll Cardiol (2005) 1.56
Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. J Cardiovasc Magn Reson (2004) 1.54
Severity of mitral and aortic regurgitation as assessed by cardiovascular magnetic resonance: optimizing correlation with Doppler echocardiography. J Cardiovasc Magn Reson (2006) 1.54
In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent. Circulation (2004) 1.53
Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol (2009) 1.48
C-reactive protein is associated with subclinical epicardial coronary calcification in men and women: the Framingham Heart Study. Circulation (2002) 1.46
CMR predictors of mitral regurgitation in mitral valve prolapse. JACC Cardiovasc Imaging (2010) 1.45
In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent. Circulation (2004) 1.45
Three-dimensional black-blood cardiac magnetic resonance coronary vessel wall imaging detects positive arterial remodeling in patients with nonsignificant coronary artery disease. Circulation (2002) 1.44
Right Ventricular Volumes and Systolic Function by Cardiac Magnetic Resonance and the Impact of Sex, Age, and Obesity in a Longitudinally Followed Cohort Free of Pulmonary and Cardiovascular Disease: The Framingham Heart Study. Circ Cardiovasc Imaging (2016) 1.42
Low-dimensional-structure self-learning and thresholding: regularization beyond compressed sensing for MRI reconstruction. Magn Reson Med (2011) 1.41
ACCF/AHA clinical competence statement on cardiac imaging with computed tomography and magnetic resonance. Circulation (2005) 1.40
Facility perception of nuclear cardiology accreditation: Results of an Intersocietal Accreditation Commission (IAC) survey. J Nucl Cardiol (2014) 1.39
Subclinical coronary and aortic atherosclerosis detected by magnetic resonance imaging in type 1 diabetes with and without diabetic nephropathy. Circulation (2006) 1.38
Age and sex distribution of subclinical aortic atherosclerosis: a magnetic resonance imaging examination of the Framingham Heart Study. Arterioscler Thromb Vasc Biol (2002) 1.38
Resveratrol improves myocardial perfusion in a swine model of hypercholesterolemia and chronic myocardial ischemia. Circulation (2010) 1.37
Right ventricular involvement in hypertrophic cardiomyopathy. Am J Cardiol (2007) 1.35
Relation between infarct size in ST-segment elevation myocardial infarction treated successfully by percutaneous coronary intervention and left ventricular ejection fraction three months after the infarct. Am J Cardiol (2010) 1.34
Computed tomography and magnetic resonance imaging of the pericardium: anatomy and pathology. Magn Reson Med Sci (2004) 1.33
Serial contrast-enhanced cardiac magnetic resonance imaging demonstrates regression of hyperenhancement within the coronary artery wall in patients after acute myocardial infarction. JACC Cardiovasc Imaging (2009) 1.32
Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol (2008) 1.31
Magnetic resonance--guided coronary artery stent placement in a swine model. Circulation (2002) 1.30
Accuracy, precision, and reproducibility of four T1 mapping sequences: a head-to-head comparison of MOLLI, ShMOLLI, SASHA, and SAPPHIRE. Radiology (2014) 1.28
Epicardial fat: definition, measurements and systematic review of main outcomes. Arq Bras Cardiol (2013) 1.24
Wavelet-domain medical image denoising using bivariate laplacian mixture model. IEEE Trans Biomed Eng (2009) 1.24
Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrin-targeted contrast agent. Circulation (2005) 1.23
Combined saturation/inversion recovery sequences for improved evaluation of scar and diffuse fibrosis in patients with arrhythmia or heart rate variability. Magn Reson Med (2014) 1.23
Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure. Am J Physiol Heart Circ Physiol (2005) 1.18
Delayed-enhancement cardiovascular magnetic resonance coronary artery wall imaging: comparison with multislice computed tomography and quantitative coronary angiography. J Am Coll Cardiol (2007) 1.17
Left atrial function and scar after catheter ablation of atrial fibrillation. Heart Rhythm (2008) 1.16
Hypertrophic cardiomyopathy: quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging. Radiology (2010) 1.16
Relationship between intended sites of RF ablation and post-procedural scar in AF patients, using late gadolinium enhancement cardiovascular magnetic resonance. Heart Rhythm (2009) 1.14
Assessment by cardiovascular magnetic resonance, electron beam computed tomography, and carotid ultrasonography of the distribution of subclinical atherosclerosis across Framingham risk strata. Am J Cardiol (2006) 1.14